Clinical Neuropharmacology

Top Research Topics at Clinical Neuropharmacology?

Internal medicine, Anesthesia, Pharmacology, Endocrinology and Psychiatry are the subjects of interest in Clinical Neuropharmacology. Internal medicine research featured in Clinical Neuropharmacology incorporates concerns from various other topics such as Gastroenterology and Schizophrenia. Clinical Neuropharmacology focuses on Anesthesia but the discussions also offer insight into other areas such as Placebo, Adverse effect and Surgery, Chemotherapy.

Discussions in Clinical Neuropharmacology are anchored in the subject of Placebo and the similar topic of Randomized controlled trial. The majority of Pharmacology studies presented zero in on Pharmacokinetics. Depression (differential diagnoses) is a major topic of Psychiatry research presented in it.

The Levodopa works, particularly on Carbidopa are tackled in Clinical Neuropharmacology. The study on Parkinson's disease presented in the journal intersects with subjects under the field of Central nervous system disease.

• Internal medicine (25.57%)
• Anesthesia (19.34%)
• Pharmacology (16.85%)

What are the most cited papers published in the journal?

• Acute spinal cord injury, part I: pathophysiologic mechanisms. (549 citations)
• Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis (535 citations)
• Pharmacological mechanisms of opioid analgesics. (508 citations)

Research areas of the most cited articles at Clinical Neuropharmacology:

The most cited articles explore disciplines such as Internal medicine, Anesthesia, Pharmacology, Parkinson's disease and Levodopa. The journal papers explore topics in Internal medicine which can be helpful for research in disciplines like Gastroenterology, Endocrinology and Psychiatry. The journal articles focus on Anesthesia but the discussions also offer insight into other areas such as Randomized controlled trial, Surgery, Chemotherapy, Adverse effect and Placebo.

What topics the last edition of the journal is best known for?

• Internal medicine
• Disease
• Diabetes mellitus

The previous edition focused in particular on these issues:

The journal focuses largely on the fields of Pediatrics, Anesthesia, Internal medicine, Adverse effect and Psychiatry. Pediatrics research presented in Clinical Neuropharmacology encompasses a variety of subjects, including Schizophrenia, Bipolar disorder, Mood, Fluoxetine and Serotonin reuptake inhibitor. In addition to Anesthesia research, Clinical Neuropharmacology aims to explore topics under Diffusion MRI, Lacosamide and Anxiety.

In it, Oncology and Depression (differential diagnoses) are investigated in conjunction with one another to address concerns in Internal medicine research. The studies on Adverse effect discussed can also contribute to research in the domains of Aripiprazole, Enuresis, Low dose and Outbreak. The work on Cohort study tackled in it brings together disciplines like Levodopa and Amantadine.

The most cited articles from the last journal are:

• Levosulpiride Relieved Persistent Hiccups in a Patient With COVID-19 and Vascular Cognitive Impairment. (1 citations)
• The Effects of Ibuprofen Consumption on the Incidence of Postpartum Depression. (1 citations)
• Muscle-Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis With Peripheral Nerve Hyperexcitability: Case Report and Literature Review. (1 citations)

Papers citation over time

A key indicator for each journal is its effectiveness in reaching other researchers with the papers published at that venue.

The chart below presents the interquartile range (first quartile 25%, median 50% and third quartile 75%) of the number of citations of articles over time.

Top authors and change over time

The top authors publishing in Clinical Neuropharmacology (based on the number of publications) are:

• Stephen I. Deutsch (49 papers) published 1 paper at the last edition,
• Abraham Weizman (43 papers) published 2 papers at the last edition, 1 more than at the previous edition,
• Richard B. Rosse (36 papers) absent at the last edition,
• Federico Micheli (32 papers) absent at the last edition,
• Jean-Louis Montastruc (28 papers) absent at the last edition.

The overall trend for top authors publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top authors.

Top affiliations and change over time

Only papers with recognized affiliations are considered

The top affiliations publishing in Clinical Neuropharmacology (based on the number of publications) are:

• National Institutes of Health (50 papers) absent at the last edition,
• United States Department of Veterans Affairs (44 papers) absent at the last edition,
• French Institute of Health and Medical Research (43 papers) absent at the last edition,
• Sapienza University of Rome (41 papers) absent at the last edition,
• University of South Florida (34 papers) published 2 papers at the last edition, 1 more than at the previous edition.

The overall trend for top affiliations publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top affiliations.

Publication chance based on affiliation

The publication chance index shows the ratio of articles published by the best research institutions in the journal edition to all articles published within that journal. The best research institutions were selected based on the largest number of articles published during all editions of the journal.

The chart below presents the percentage ratio of articles from top institutions (based on their ranking of total papers).Top affiliations were grouped by their rank into the following tiers: top 1-10, top 11-20, top 21-50, and top 51+. Only articles with a recognized affiliation are considered.

During the most recent 2021 edition, 38.71% of publications had an unrecognized affiliation. Out of the publications with recognized affiliations, 10.53% were posted by at least one author from the top 10 institutions publishing in the journal. Another 2.63% included authors affiliated with research institutions from the top 11-20 affiliations. Institutions from the 21-50 range included 18.42% of all publications and 68.42% were from other institutions.

Returning Authors Index

A very common phenomenon observed among researchers publishing scientific articles is the intentional selection of journals they have already attended in the past. In particular, it is worth analyzing the case when the authors participate in the same journal from year to year.

The Returning Authors Index presented below illustrates the ratio of authors who participated in both a given as well as the previous edition of the journal in relation to all participants in a given year.

Returning Institution Index

The graph below shows the Returning Institution Index, illustrating the ratio of institutions that participated in both a given and the previous edition of the conference in relation to all affiliations present in a given year.

The experience to innovation index

Our experience to innovation index was created to show a cross-section of the experience level of authors publishing in a journal. The index includes the authors publishing at the last edition of a journal, grouped by total number of publications throughout their academic career (P) and the total number of citations of these publications ever received (C).

The group intervals were selected empirically to best show the diversity of the authors' experiences, their labels were selected as a convenience, not as judgment. The authors were divided into the following groups:

• Novice - P < 5 or C < 25 (the number of publications less than 5 or the number of citations less than 25),
• Competent - P < 10 or C < 100 (the number of publications less than 10 or the number of citations less than 100),
• Experienced - P < 25 or C < 625 (the number of publications less than 25 or the number of citations less than 625),
• Master - P < 50 or C < 2500 (the number of publications less than 50 or the number of citations less than 2500),
• Star - P ≥ 50 and C ≥ 2500 (both the number of publications greater than 50 and the number of citations greater than 2500).

The chart below illustrates experience levels of first authors in cases of publications with multiple authors.

Career Opportunities in Clinical Neuropharmacology

Another critical aspect to explore in Clinical Neuropharmacology is the various career opportunities and education requirements within the field. Given the interdisciplinary nature of the subject, students and professionals can pursue a wide array of careers in healthcare, research, and academia. For example, Nurse Practitioners (NPs) specializing in Neuropharmacology can work in neurology departments, clinics, research institutions, and educational settings. They can provide patient care, conduct research, and educate patients and families about neurological disorders. NPs who specialize in neuropharmacy must meet certain education and licensure requirements, including a master's degree in nursing, national certification, state licensure, and clinical experience. Professionals interested in becoming a Nurse Practitioner in Kansas should review the specific nurse practitioner education requirements in Kansas to ensure they meet all the necessary qualifications. Besides, they need to familiarize themselves with pharmacology concepts, patient care techniques, and research methods specific to neurology. Clinical Neuropharmacology also potentially opens doors for researchers interested in exploring the connection between neurological disorders and pharmacology. They may contribute to the development of new treatments or improve existing therapeutic methods for neurological diseases. Furthermore, lecturers and educators can profoundly influence the next generation of professionals in the field. Regardless of the career path, thorough preparation, dedication, and a strong interest in neuroscience and pharmacology are essential for success in Clinical Neuropharmacology.